Grupo-Publicaciones-GIIS026

Krämer A, Bochtler T, Pauli C, Shiu KK, Cook N, de Menezes JJ, Pazo-Cid RA, Losa F, Robbrecht DG, Tomášek J, Arslan C, Özgüroğlu M, Stahl M, Bigot F, Kim SY, Naito Y, Italiano A, Chalabi N, Durán-Pacheco G, Michaud C, Scarato J, Thomas M, Ross JS, Moch H, Mileshkin L. Molecularly guided therapy versus chemotherapy after disease control in unfavourable cancer of unknown primary (CUPISCO): an open-label, randomised, phase 2 study. Lancet. 2024 Aug 10;404(10452):527-539. doi: 10.1016/S0140-6736(24)00814-6. Epub 2024 Jul 31. PMID: 39096924. FI-98,4

Wang X, Danenberg E, Huang C, Egle D, Callari M, Bermejo B, Dugo M, Zamagni C, Thill M, Antón Torres A, Zambelli S, Russo S, Ciruelos E, Greil R, Gyorffy B, Semiglazov V, Colleoni M, Kelly C, Mariani G, Del Mastro L, Biasi O, Seitz R, Valagussa P, Viale G, Gianni L, Bianchini G, Ali H. Spatial predictors of immunotherapy response in triple-negative breast cancer. NATURE. 2023. 10.1038/s41586-023-06498-3. FI-50,5

Janjigian Y, Ajani J, Moehler M, Shen L, Garrido M, Gallardo C, Wyrwicz L, Yamaguchi K, Cleary J, Elimova E, Karamouzis M, Bruges R, Skoczylas T, Bragagnoli A, Liu T, Tehfe M, Zander T, Kowalyszyn R, Pazo Cid R, Schenker M, Feeny K, Wang R, Lei M, Chen C, Nathani R, Shitara K. First-Line Nivolumab Plus Chemotherapy for Advanced Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: 3-Year Follow-Up of the Phase III CheckMate 649 Trial.. JOURNAL OF CLINICAL ONCOLOGY. 2024. 10.1200/JCO.23.01601. FI-42,1

Hegewisch-Becker S, Mendez G, Chao J, Nemecek R, Feeney K, Van Cutsem E, Al-Batran S, Mansoor W, Maisey N, Pazo Cid R, Burge M, Perez-Callejo D, Hipkin R, Mukherjee S, Lei M, Tang H, Suryawanshi S, Kelly R, Tebbutt N. First-Line Nivolumab and Relatlimab Plus Chemotherapy for Gastric or Gastroesophageal Junction Adenocarcinoma: The Phase II RELATIVITY-060 Study.. JOURNAL OF CLINICAL ONCOLOGY. 2024. 10.1200/JCO.23.01636. FI-42,1

Moehler M, Xiao H, Blum S, Elimova E, Cella D, Shitara K, Ajani J, Janjigian Y, Garrido M, Shen L, Yamaguchi K, Liu T, Schenker M, Kowalyszyn R, Bragagnoli A, Bruges R, Montesarchio V, Pazo Cid R, Hunter S, Davenport E, Wang J, Kondo K, Li M, Wyrwicz L. Health-Related Quality of Life With Nivolumab Plus Chemotherapy Versus Chemotherapy in Patients With Advanced Gastric/Gastroesophageal Junction Cancer or Esophageal Adenocarcinoma From CheckMate 649. JOURNAL OF CLINICAL ONCOLOGY. 2023. 10.1200/JCO.23.00170. FI-42,1

Lluch A, Barrios C, Torrecillas L, Ruiz-Borrego M, Bines J, Segalla J, Guerrero-Zotano Á, García-Sáenz J, Torres R, de la Haba J, García-Martínez E, Gómez H, Llombart A, Bofill J, Baena-Cañada J, Barnadas A, Calvo L, Pérez-Michel L, Ramos M, Fernández I, Rodríguez-Lescure Á, Cárdenas J, Vinholes J, Martínez de Dueñas E, Godes M, Seguí M, Antón Torres A, López-Álvarez P, Moncayo J, Amorim G, Villar E, Reyes S, Sampaio C, Cardemil B, Escudero M, Bezares S, Carrasco E, Martín M, GEICAM Spanish Breast Cancer Group , CIBOMA (Iberoamerican Coalition for Research in Breast Oncology) , LACOG (Latin American Cooperative Oncology Group) . Phase III Trial of Adjuvant Capecitabine After Standard Neo-/Adjuvant Chemotherapy in Patients With Early Triple-Negative Breast Cancer (GEICAM/2003-11_CIBOMA/2004-01).. JOURNAL OF CLINICAL ONCOLOGY. 2020. 10.1200/JCO.19.00904. FI-42,1

Van Laethem J, Borbath I, Prenen H, Geboes K, Lambert A, Mitry E, Cassier P, Blanc J, Pilla L, Batlle J, Garrote M, Pazo Cid R, Gallego I, Smith K, Ellmark P, de Coana Y, Ambarkhane S, Macarulla T. Combining CD40 agonist mitazalimab with mFOLFIRINOX in previously untreated metastatic pancreatic ductal adenocarcinoma (OPTIMIZE-1): a single-arm, multicentre, phase 1b/2 study. LANCET ONCOLOGY. 2024. 10.1016/S1470-2045(24)00263-8. FI-41,6

Martin-Broto J, Martinez-Garcia J, Moura D, Redondo A, Gutierrez A, Lopez-Pousa A, Martínez Trufero J, Sevilla I, Diaz-Beveridge R, Solis-Hernandez M, Carnero A, Perez M, Marcilla D, Garcia-Foncillas J, Romero P, Fernandez-Jara J, Lopez-Lopez D, Arribas I, Hindi N. Phase II trial of CDK4/6 inhibitor palbociclib in advanced sarcoma based on mRNA expression of CDK4/ CDKN2A.. Signal Transduction and Targeted Therapy. 2023. 10.1038/s41392-023-01661-8. FI-40,8

Martin-Broto J, Valverde C, Hindi N, Vincenzi B, Martínez Trufero J, Grignani G, Italiano A, Lavernia J, Vallejo A, Tos P, Le Loarer F, Gonzalez-Campora R, Ramos R, Hernandez-Jover D, Gutiérrez Dalmau A, Serrano C, Monteagudo M, Leton R, Robledo M, Moura D, Martin-Ruiz M, Lopez-Guerrero J, Cruz J, Fernandez-Serra A, Blay J, Fumagalli E, Martinez-Marin V. REGISTRI: Regorafenib in first-line of KIT/PDGFRA wild type metastatic GIST: a collaborative Spanish (GEIS), Italian (ISG) and French Sarcoma Group (FSG) phase II trial. Molecular Cancer. 2023. 10.1186/s12943-023-01832-9. FI-27,7

Martin-Broto J, Redondo A, Moura D, Valverde C, Manuel Morales J, Lopez-Pousa A, Martínez Trufero J, Gutierrez A, Diaz-Beveridge R, Luna P, Martinez-Marin V, Marcilla D, Arribas I, Ledesma P, Antonio Lopez-Martin J, Di Lernia D, Zamora J, Hindi N. A phase II trial of weekly nab-paclitaxel for progressive and symptomatic desmoid tumors. Nature Communications. 2022. 10.1038/s41467-022-33975-6. FI-14,7